Moderna wins FDA approval for the world’s first mRNA flu vaccine

Every flu season, influenza hospitalizes hundreds of thousands of adults worldwide. Now, for the first time, an mRNA-based vaccine has been approved to fight it. The U.S. Food and Drug Administration has approved Moderna's mFLUSIVA, making it the first mRNA flu vaccine to clear a major regulatory authority anywhere in the world.

The approval covers adults aged 50 and older. For the 50 to 64 age group, approval was based on a Phase 3 trial across 11 countries involving more than 40,000 participants. For adults 65 and older, it was granted under accelerated approval, tied to immune response data, with a confirmatory postmarketing trial still to come.

Moderna CEO Stéphane Bancel called it a demonstration of "the continued strength and versatility" of the company's mRNA platform. mFLUSIVA is now Moderna's fourth FDA-approved product, joining Spikevax, mRESVIA, and mNEXSPIKE. The company expects supply to reach select U.S. retailers ahead of the 2026-2027 respiratory season.

How does it work?

Like Moderna's COVID-19 vaccines, mFLUSIVA uses messenger RNA technology to instruct the body to produce an immune response. It targets both influenza A subtypes and type B strains. The Phase 3 trial measured its performance against a standard-dose inactivated flu vaccine, evaluating both safety and relative vaccine efficacy against lab-confirmed influenza-like illness. No new safety concerns were identified. Side effects reported were consistent with other mRNA vaccines, including injection site reactions, fatigue, headache, and muscle pain.

Why does it matter?

Flu is not a minor inconvenience. It kills between 290,000 and 650,000 people globally each year, according to the WHO. Traditional flu vaccines are reformulated annually and have variable effectiveness. mRNA technology allows faster updates to match circulating strains, which could improve protection year over year. For GCC health authorities managing large aging expatriate and citizen populations, this approval signals that mRNA-based flu vaccines may soon be part of national immunisation strategies. Saudi Arabia's Vision 2030 health targets and the UAE's broader push toward preventive care both create strong policy reasons to watch this space closely.

The context

Regulatory submissions for mFLUSIVA are already under review in the European Union, Canada, and Australia. Moderna has also signalled plans for submissions in additional markets during 2026, which would likely include Gulf states. The GCC has been an active early adopter of mRNA COVID vaccines, and several member states have existing procurement relationships with Moderna. So this approval is not an abstract milestone for the region. It's the opening of a regulatory and procurement conversation that health ministries across the Arab world will need to prepare for.